{"schema_version":"secwatch.filing_event.v1","accession":"0000937556-24-000040","form_type":"8-K","ticker":"MASI","cik":"0000937556","company_name":"MASIMO CORP","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.559482+00:00","generated_at":"2026-06-02T21:34:52.099579+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Masimo Q1 rev $492.8M (healthcare $339.6M), GAAP EPS $0.35, Non-GAAP $0.77; lifts FY2024 outlook","bullets":["Consolidated Q1 revenue $492.8M; healthcare $339.6M, non-healthcare $153.2M.","GAAP net income $18.9M ($0.35 diluted EPS); non-GAAP net income $41.9M ($0.77 diluted EPS).","Sensor manufacturing shift from Mexico to Malaysia improved healthcare gross margins ahead of schedule.","Raises FY2024 healthcare revenue guidance to $1.355-1.385B and non-GAAP EPS to $3.54-3.70.","Pursuing separation of consumer business; management finalizing structure for board review."],"urls":{"canonical":"https://secwatch.observer/filing/0000937556-24-000040","json":"https://secwatch.observer/filing/0000937556-24-000040.json","markdown":"https://secwatch.observer/filing/0000937556-24-000040.md","text":"https://secwatch.observer/filing/0000937556-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000040/0000937556-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000040/masi-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:34:52.099579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2693e27a4fdd650e5652755b48a83aa541b14d5","claim":"MASIMO CORP reported first quarter ended March 30, 2024 results: revenue $492.8 million, net income $18.9 million, EPS $0.35 per diluted share. Guidance raised.","evidence_excerpt":"by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Masimo Reports First Quarter 2024 Financial Results First Quarter 2024 Highlights: • Consolidated revenue was $492.8 million; • Healthcare revenue was $339.6 million; • Non-healthcare revenue was $153.2 million; • GAAP net income per diluted share was $0.35; and • Non-GAAP net income per diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000040/0000937556-24-000040-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 30, 2024"},{"label":"Revenue","value":"$492.8 million"},{"label":"Net income","value":"$18.9 million"},{"label":"EPS","value":"$0.35 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}